Skip to content

A Portable Thoracic Impedance Device for Detecting Pulmonary Congestion in Heart Failure Patients

A Portable Thoracic Impedance Device for Detecting Pulmonary Congestion in Heart Failure Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06604468
Acronym
DISPLAID1
Enrollment
30
Registered
2024-09-19
Start date
2025-09-01
Completion date
2026-09-01
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

bioimpedance, heart failure, diuretic treatment, fluid management

Brief summary

This study investigates a portable thoracic bioimpedance tomography (TBIT) device designed to detect early lung congestion in heart failure patients. The main goal is to evaluate how well the device's measurements match those obtained from lung ultrasound and other imaging techniques. By detecting lung fluid build-up before symptoms worsen, this device could help manage heart failure more effectively outside of hospital settings, potentially improving patient care and reducing hospital admissions. Participants in the study are monitored using this device along with standard imaging methods, and data on heart failure symptoms are collected to understand the device's accuracy and usability.

Detailed description

The primary objective is to determine the correlation between TBIT measurements and B-line scores obtained via portable lung ultrasound, with secondary objectives including correlations with thoracic water content from high-resolution CT scans, heart failure symptoms, and NT-proBNP levels adjusted for renal function. Conducted as a prospective, cross-sectional diagnostic study, the research involves heart failure patients recruited during hospital admissions or outpatient visits at heart failure and nephrology clinics. Data collected include TBIT, ultrasound, and CT imaging results, clinical data on heart failure severity, and symptom questionnaires. The study will assess correlations using statistical models such as Spearman's correlation coefficient and mixed-effects models, aiming to validate TBIT as a non-invasive, cost-effective tool for early detection of pulmonary congestion, potentially improving outpatient management and reducing heart failure-related hospitalizations. Ethical considerations include informed consent, confidentiality measures, and ensuring participant safety, with the study procedures being observational and not altering patient treatment based on TBIT results.

Interventions

DIAGNOSTIC_TESTThoracic bioimpedance tomography

Data collection using a thoracic bioimpedance tomography device

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults aged 18 years or older. * Diagnosed with heart failure, defined by the following criterion: hospitalization or an emergency visit for decompensated heart failure (pulmonary edema) within the last 12 months.

Exclusion criteria

* Pregnant women at the time of eligibility evaluation. * Presence of an implanted electronic device in the thorax, such as a pacemaker or defibrillator. * Inability to provide informed consent. * Admission to intensive care or the coronary care unit.

Design outcomes

Primary

MeasureTime frameDescription
Lung congestionBaseline, week 4, week 8Assessed using lung ultrasound over 12 thoracic zones to calculate the B-line score

Secondary

MeasureTime frameDescription
Thoracic water contentBaselineDerived using high resolution CT-scan images
Symptom burdenBaseline, week 4 and week 8Assessed using the KCCQ-12 questionnaire
NT-pro-BNPBaseline, week 4, week 8Measurement of NT-pro-BNP

Other

MeasureTime frameDescription
Episodes of decompensated heart failure90 daysUrgent visit or hospitalisation for worsening of heart failure symptoms requiering diuretic treatment or dialysis

Countries

Canada

Contacts

Primary ContactWilliam Beaubien-Souligny, MD PhD
william.beaubien-souligny.med@ssss.gouv.qc.ca15148908000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026